Insulet Q3 2025 Results Exceed Expectations, Omnipod Expansion, and Upgraded Guidance Drive Strong Valuation

Saturday, Nov 8, 2025 3:31 am ET1min read

Insulet delivered Q3 2025 results surpassing analyst predictions due to strong Omnipod expansion. The company boosted full-year guidance, with shares rallying and guidance continually raised. The stock is now undervalued at $365.96, with room for upside based on updated growth and margin expectations. However, reliance on a single core product and global competition pose risks to Insulet's growth story.

Insulet Q3 2025 Results Exceed Expectations, Omnipod Expansion, and Upgraded Guidance Drive Strong Valuation

Comments



Add a public comment...
No comments

No comments yet